• A whole-animal platform to advance a clinical kinase inhibitor into new disease space
• Multi-targeting Drug Community Challenge

Scientists from one of the Pilot Centers for Precision Disease Modeling funded by ORIP (Icahn School of Medicine at Mount Sinai, NY), are developing drug-based therapeutics that target abnormal networks. They reported discovery of a new class of “tumor-calibrated inhibitors” with strongly improved therapeutic index in fly and human cancer xenograft models. This approach may also prove useful in drug development strategies outside of oncology, such as neural and cardiovascular diseases.

Authors published a Concept article introducing a new DREAM Challenge to help realize the promise of their rational polypharmacology approach.